GlassScriptPhysician profile
Immanuel Hsu
NPI 1669908992
$1,433.41
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $241 · 2021: $960 · 2022: $232.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.14 | 2020-2021 | |
| Amarin Pharma, INC. | $183.75 | 2020-2021 | |
| Lilly USA, LLC | $140.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.15 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $127.72 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $109.06 | 2020-2021 | |
| Astellas Pharma US INC | $74.10 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $69.70 | 2020-2021 | |
| Glaxosmithkline, LLC. | $62.29 | 2021-2022 | |
| Bardy Diagnostics, INC. | $46.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.64 | 2021 | |
| Genentech USA, INC. | $30.98 | 2020-2021 | |
| Abbvie INC. | $28.61 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.98 | 2022 | |
| Scynexis, INC. | $23.17 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.67 | 2021 | |
| Pfizer INC. | $20.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.22 | 2021 | |
| Phadia US INC. | $15.20 | 2021 | |
| Horizon Therapeutics Plc | $13.97 | 2021 | |
| Medtronic, INC. | $12.63 | 2021 | |
| Merck Sharp & Dohme LLC | $11.85 | 2021 | |
| Allergan, INC. | $11.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Immanuel Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.